SEP-363856
Рандомизированное, двойное слепое исследование с использованием активного препарата в качестве контроля для оценки безопасности при длительном применении и переносимости препарата SEP-363856 у пациентов с шизофренией
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/688/2019-12-02/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–65 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 180 чел. в стране «Россия».
- Центров в реестре: 14 в 10 городах. Список — ниже на странице.
- Плановая дата окончания (12.2022) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 9 · невключение: 11
Критерии включения
- The main inclusion criteria include, but are not limited to the following:
- Male or female participant between 18 to 65 years of age (inclusive) at the time of consent.
- Participant meets DSM-5 criteria for a diagnosis of schizophrenia as established by clinical interview at screening (using the DSM-5 as a reference and confirmed using the SCID-CT). The time since the participant's diagnosis must be ≥ 1 year prior to Screening.
- Participant must have a CGI-S score ≤ 4 at Screening and Baseline.
- Participant must have a PANSS total score ≤ 80 at Screening and Baseline.
- Participant is judged to be clinically stable (i.e., no evidence of an acute exacerbation) by the Investigator for at least 8 weeks prior to Screening.
- Participant has had no change in antipsychotic medication(s) (minor dose adjustments for tolerability purposes are permitted) for at least 6 weeks prior to Screening.
- Participants taking an antipsychotic agent at Screening may participate in this study only if there are signs of intolerability or lack of efficacy of the current antipsychotic (as determined by the Investigator).
- Participant is, in the opinion of the Investigator, generally healthy based on Screening medical history, PE, neurological examination, vital signs, electrocardiogram (ECG) and clinical laboratory values (hematology, chemistry and urinalysis).
Критерии невключения
- Main exclusion criteria include, but are not limited to:
- Participant was hospitalized for a psychiatric illness within the 8 weeks prior to Screening.
- Participant has a current DSM-5 diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, or lifetime history of significant substance abuse that, in the opinion of the Investigator or Sponsor, may have had a significant and potentially permanent impact on the brain or other body systems, major depressive disorder, schizoaffective disorder, ,bipolar I or II disorder, obsessive compulsive disorder, and posttraumatic stress disorder, symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as theses symptoms are not the primary focus of treatment.
- Participant is judged to be resistant to antipsychotic treatment by the Investigator, based on failure to respond to 2 or more marketed antipsychotic agents within a 1-year period prior to Screening, given at adequate dose as per labeling, for at least 4 weeks.
- Participant answers "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at Screening (i.e., in the past one month) or at Baseline (i.e., since last visit).
- Participant is at significant risk of harming self or others based on Investigator's judgment.
- Participant has attempted suicide within 6 months prior to Screening.
- Participant has received treatment with a psychotropic medication or herbal supplement within 3 days or 5 half-lives (whichever is longer)
- Participant has been treated with quetiapine or quetiapine XR within the 6 weeks prior to Screening or has a history of inadequate response or intolerability to quetiapine or quetiapine XR.
- Participant has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the participant's ability to complete and/or participate in the study.
- Participant has any clinically significant abnormal laboratory value(s) at Screening as determined by investigator.
Источник: ClinicalTrials.gov, NCT04115319 · запись обновлена в реестре 31 декабря 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (1)
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation — From first dose of the study drug up to 7 days after last dose of study drug (Up to 53 weeks)
Цель исследования
A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia.
This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers worldwide. The study will last approximately 57 weeks.
Области и заболевания
Где проходит
14 центров в 10 городах- Санкт-Петербургское ГБУ «Психоневрологический диспансер № 10»
- СПб ГБУЗ «Психоневрологический диспансер № 1»
- СПб ГБУЗ «Психоневрологический диспансер № 5»
- Санкт-Петербургское ГУЗ «Психиатрическая больница Святого Николая Чудотворца»
- ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава России
Откуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 688 от 02.12.2019 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик, центры
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04115319 Официальный реестр (США) · загружено 9 ноября 2026Цель
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.